Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

por Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Publicado 2021

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer

por Shogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, Akifumi Notsu
Publicado 2021